within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02A_AntiadrenergicAgentsCentrallyActing.C02AC06_Rilmenidine;

model Rilmenidine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.72,
    Cl = 1.4722222222222223e-06,
    adminDuration = 600,
    adminMass = 1 / 1000000,
    adminCount = 1,
    Vd = 0.049,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01983333333333333,
    Tlag = 10.799999999999999);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Rilmenidine</td></tr><tr><td>ATC code:</td><td>C02AC06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>49</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5.3</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Rilmenidine is a centrally acting antihypertensive agent of the imidazoline receptor agonist class. It is primarily used for the treatment of mild to moderate essential hypertension. It acts mainly through stimulation of imidazoline receptors in the brainstem, leading to a reduction of sympathetic outflow and subsequent decrease in blood pressure. Rilmenidine is approved and used in several countries, particularly in Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following single oral dose administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C02AC06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Rilmenidine;
